Cancer, everyone hates the word. The disease kills and the treatment debilities. Patients suffer as they battle with chemotherapy and radiation. Since 1998 Seattle Genetics and Dr. Clay Siegall have been trying to ease this suffering through antibody based therapies, called antibody-drug conjugates. These therapies work by having the patient’s own antibodies target cancer cells while leaving the rest of the body healthy. Imagine the possibilities of cancer treatment without fatigue, nausea, or nerve damage. This advancement in medicine would make having cancer more tolerable for patients and caregivers.
Currently Seattle Genetics has twenty antibody-drug conjugates in clinical development but the two super stars are ADCETRIS® (rituximab vedotin) and SGN-CD33A. ADCETRIS® is designed to fight lymphoma and has already been used on more than 15,000 patients in more than 60 countries. Seattle Genetics is hopeful that ADCETRIS® will prevent relapses following stem cell transplants which is fantastic news since 50 percent of patients are at risk for this. The other therapy is SGN-CD33A. It was designed to fight a cancer that has had the same bleak survival rate for the last 30 years, acute myeloid leukemia. At this time the SGN-CD33A is showing encouraging data in clinical trials. ADCETRIS® and SGN-CD33A are just a part of the advances being made by Seattle Genetics.
The chief motivation that drives Seattle Genetics and Dr. Clay Siegall is improving the lives of cancer patients. Cancer is a lifelong condition that survivors must continue to fight for the rest of their lives. Through antibody-drug conjugates created by Seattle Genetics this fight can be alleviated. Making the quality of life better while extending the quantity.